<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Sousa TDC</submitter><funding>Conselho Nacional de Desenvolvimento Científico e Tecnológico</funding><funding>Coordenação de Aperfeiçoamento de Pessoal de Nível Superior</funding><funding>Ministério da Saúde</funding><pagination>944277</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9516282</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>10</volume><pubmed_abstract>The influenza A virus (IAV) is of a major public health concern as it causes annual epidemics and has the potential to cause pandemics. At present, the neuraminidase inhibitors (NAIs) are the most widely used anti-influenza drugs, but, more recently, the drug baloxavir marboxil (BXM), a polymerase inhibitor, has also been licensed in some countries. Mutations in the viral genes that encode the antiviral targets can lead to treatment resistance. Worldwide, a low prevalence of antiviral resistant strains has been reported. Despite that, this situation can change rapidly, and resistant strain surveillance is a priority. Thus, the aim of this was to evaluate Brazilian IAVs antiviral resistance from 2017 to 2019 through the identification of viral mutations associated with reduced inhibition of</pubmed_abstract><journal>Frontiers in public health</journal><pubmed_title>Low prevalence of influenza A strains with resistance markers in Brazil during 2017-2019 seasons.</pubmed_title><pmcid>PMC9516282</pmcid><funding_grant_id>401851/2015-0</funding_grant_id><pubmed_authors>Rodrigues RR</pubmed_authors><pubmed_authors>Motta F</pubmed_authors><pubmed_authors>Martins JSCC</pubmed_authors><pubmed_authors>de Almeida WAF</pubmed_authors><pubmed_authors>Garcia CC</pubmed_authors><pubmed_authors>Siqueira MM</pubmed_authors><pubmed_authors>Brown D</pubmed_authors><pubmed_authors>Resende PC</pubmed_authors><pubmed_authors>Debur MDC</pubmed_authors><pubmed_authors>Santos KCO</pubmed_authors><pubmed_authors>Cavalcanti AC</pubmed_authors><pubmed_authors>Gregianini TS</pubmed_authors><pubmed_authors>Ferreira JA</pubmed_authors><pubmed_authors>Santos CA</pubmed_authors><pubmed_authors>Fernandes SB</pubmed_authors><pubmed_authors>Sousa TDC</pubmed_authors><pubmed_authors>Pereira FM</pubmed_authors><pubmed_authors>Miranda MD</pubmed_authors><pubmed_authors>Matos ADR</pubmed_authors><pubmed_authors>Iani FCM</pubmed_authors></additional><is_claimable>false</is_claimable><name>Low prevalence of influenza A strains with resistance markers in Brazil during 2017-2019 seasons.</name><description>The influenza A virus (IAV) is of a major public health concern as it causes annual epidemics and has the potential to cause pandemics. At present, the neuraminidase inhibitors (NAIs) are the most widely used anti-influenza drugs, but, more recently, the drug baloxavir marboxil (BXM), a polymerase inhibitor, has also been licensed in some countries. Mutations in the viral genes that encode the antiviral targets can lead to treatment resistance. Worldwide, a low prevalence of antiviral resistant strains has been reported. Despite that, this situation can change rapidly, and resistant strain surveillance is a priority. Thus, the aim of this was to evaluate Brazilian IAVs antiviral resistance from 2017 to 2019 through the identification of viral mutations associated with reduced inhibition of</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022</publication><modification>2026-04-08T11:46:33.005Z</modification><creation>2024-12-03T20:25:25.215Z</creation></dates><accession>S-EPMC9516282</accession><cross_references><pubmed>36187691</pubmed><doi>10.3389/fpubh.2022.944277</doi></cross_references></HashMap>